Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-escalation study of tralokinumab in Japanese patients with idiopathic pulmonary fibrosis
jRCT2080222402Phase 2
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tralokinumab in idiopathic pulmonary fibrosis (IPF) (2 cohorts), sponsored by AstraZeneca.
02
Drugs
tralokinumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2080222402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222402.